METHOD FOR TREATING NONTUBERCULOUS MYCOBACTERIAL INFECTION
The present invention relates to an inhalable pharmaceutical composition comprising clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt or a polymorph of clofazimine, or combination thereof, and a pharmaceutically acceptable carrier and/or excipient for use in the treatment or prophylaxis of a nontuberculous bacterial infection of the lungs, wherein clofazimine is in an amount of 1 mg to 20 mg wt % in the composition, and wherein the inhalable pharmaceutical composition is provided by inhalation in an effective daily dose of up to 90 mg of clofazimine. There is also provided pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation for administration alone, or concomitantly with other drugs as combination therapy in the treatment and/or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.
1 . An inhalable pharmaceutical composition comprising clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt, or a polymorph of clofazimine, or combination thereof, and a pharmaceutically acceptable carrier and/or excipient for use in the treatment or prophylaxis of a nontuberculous bacterial infection of the lungs, wherein clofazimine is in an amount of 1 mg to 20 mg wt % in the composition, and wherein the inhalable pharmaceutical composition is provided by inhalation in an effective daily dose of up to 90 mg of clofazimine.
2 . The inhalable pharmaceutical composition of claim 1 , wherein the nontuberculous bacterial infection of the lungs treated or prophylactically dissuaded is caused by a Mycobacterium selected from the group consisting of: Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessus , and Mycobacterium leprae , and a combination thereof.
3 . The inhalable pharmaceutical composition of claim 1 , wherein the nontuberculous bacterial infection is an opportunistic infection, selected from the group consisting of: Mycobacterium avium complex pulmonary disease and opportunistic nontuberculous infection, or combination thereof, concomitant with one or more of the group consisting of: cystic fibrosis, chronic obstructive pulmonary disease or acquired immune deficiency syndrome.
4 . The inhalable pharmaceutical composition of claim 3 , wherein the infection is an opportunistic nontuberculous mycobacteria infection in a patient with cystic fibrosis.
5 . The inhalable pharmaceutical composition of claim 1 wherein the infection treated or prophylactically dissuaded is caused by mycobacteria or other gram positive bacteria, and is administered by inhalation, before, simultaneously, or subsequent to the administration of an agent selected from the group consisting of: bedaquiline, or a pharmaceutically acceptable salt of derivative thereof, cefoxitine, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-amino salicylate, and mixtures thereof.
6 . The inhalable pharmaceutical composition of claim 1 , wherein the clofazimine is at least about 90% orthorhombic polymorph III.
7 . The inhalable pharmaceutical composition of claim 6 wherein such composition is used to treat or as a prophylaxis against a nontuberculous bacterial infection of the lungs.
8 . The inhalable pharmaceutical composition of claim 1 , wherein the composition is delivered by inhalation for treatment or prophylaxis with a high lung deposition rate of at least about 30%.
9 . An inhalable pharmaceutical composition comprising clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt, or a polymorph of clofazimine, or combination thereof, and a pharmaceutically acceptable carrier and/or excipient for use in the treatment or prophylaxis of a nontuberculous bacterial infection of the lungs, wherein clofazimine is in an amount of 1 mg to 20 mg wt % in the composition, and is delivered by an inhaler configured to cause high lung deposition rates of at least 30%.
10 . The inhalable pharmaceutical composition of claim 1 , wherein said clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt, or a polymorph of clofazimine, comprises clofazimine.
11 . The inhalable pharmaceutical composition of claim 1 , wherein said clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt, or a polymorph of clofazimine, comprises a pharmaceutically acceptable derivative of clofazimine.
12 . The inhalable pharmaceutical composition of claim 1 , wherein said clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt, or a polymorph of clofazimine, comprises a clofazimine salt.
13 . The inhalable pharmaceutical composition of claim 1 , wherein said clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt, or a polymorph of clofazimine, comprises a polymorph of clofazimine.